FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2161451182> ?p ?o ?g. }

• W2161451182 abstract "Abstract Background Chemotherapy induced nausea and vomiting (CINV) remains a major problem that seriously impairs the quality of life (QoL) in cancer patients receiving chemotherapy regimens. Complementary medicines, including homeopathy, are used by many patients with cancer, usually alongside with conventional treatment. A randomized, placebo-controlled Phase III study was conducted to evaluate the efficacy of a complex homeopathic medicine, Cocculine, in the control of CINV in non-metastatic breast cancer patients treated by standard chemotherapy regimens. Methods Chemotherapy-naïve patients with non-metastatic breast cancer scheduled to receive 6 cycles of chemotherapy including at least three initial cycles of FAC 50, FEC 100 or TAC were randomized to receive standard anti-emetic treatment plus either a complex homeopathic remedy ( Cocculine , registered in France for treatment of nausea and travel sickness) or the matching placebo (NCT00409071 clinicaltrials.gov ). The primary endpoint was nausea score measured after the 1 st chemotherapy course using the FLIE questionnaire (Functional Living Index for Emesis) with 5-day recall. Secondary endpoints were: vomiting measured by the FLIE score, nausea and vomiting measured by patient self-evaluation (EVA) and investigator recording (NCI-CTC AE V3.0) and treatment compliance. Results From September 2005 to January 2008, 431 patients were randomized: 214 to Cocculine (C) and 217 to placebo (P). Patient characteristics were well-balanced between the 2 arms. Overall, compliance to study treatments was excellent and similar between the 2 arms. A total of 205 patients (50.9%; 103 patients in the placebo and 102 in the homeopathy arms) had nausea FLIE scores > 6 indicative of no impact of nausea on quality of life during the 1 st chemotherapy course. There was no difference between the 2 arms when primary endpoint analysis was performed by chemotherapy stratum; or in the subgroup of patients with susceptibility to nausea and vomiting before inclusion. In addition, nausea, vomiting and global emesis FLIE scores were not statistically different at any time between the two study arms. The frequencies of severe (Grade ≥ 2) nausea and vomiting were low in our study (nausea: P: 17.6% vs C: 15.7%, p=0.62; vomiting: P: 10.8% vs C: 12.0%, p=0.72 during the first course). Conclusion This double-blinded, placebo-controlled, randomised Phase III study showed that adding a complex homeopathic medicine (Cocculine) to standard anti-emetic prophylaxis does not improve the control of CINV in early breast cancer patients." @default.
• W2161451182 created "2016-06-24" @default.
• W2161451182 creator A5018378577 @default.
• W2161451182 creator A5018425028 @default.
• W2161451182 creator A5019588141 @default.
• W2161451182 creator A5019999619 @default.
• W2161451182 creator A5021493534 @default.
• W2161451182 creator A5030957656 @default.
• W2161451182 creator A5041410352 @default.
• W2161451182 creator A5044903892 @default.
• W2161451182 creator A5050228664 @default.
• W2161451182 creator A5056064173 @default.
• W2161451182 creator A5073713547 @default.
• W2161451182 creator A5089385974 @default.
• W2161451182 date "2012-12-01" @default.
• W2161451182 modified "2023-09-27" @default.
• W2161451182 title "Can treatment with Cocculine improve the control of chemotherapy-induced emesis in early breast cancer patients? A randomized, multi-centered, double-blind, placebo-controlled Phase III trial" @default.
• W2161451182 cites W1487842335 @default.
• W2161451182 cites W1557364596 @default.
• W2161451182 cites W1603749121 @default.
• W2161451182 cites W1970052352 @default.
• W2161451182 cites W1984152751 @default.
• W2161451182 cites W1987115839 @default.
• W2161451182 cites W1994517392 @default.
• W2161451182 cites W2002347981 @default.
• W2161451182 cites W2020758186 @default.
• W2161451182 cites W2022083122 @default.
• W2161451182 cites W2024218621 @default.
• W2161451182 cites W2026696272 @default.
• W2161451182 cites W2033698570 @default.
• W2161451182 cites W2061936275 @default.
• W2161451182 cites W2070747741 @default.
• W2161451182 cites W2089750290 @default.
• W2161451182 cites W2095856174 @default.
• W2161451182 cites W2116682901 @default.
• W2161451182 cites W2116955650 @default.
• W2161451182 cites W2122202911 @default.
• W2161451182 cites W2132184189 @default.
• W2161451182 cites W2136818862 @default.
• W2161451182 cites W2157073178 @default.
• W2161451182 cites W2158036326 @default.
• W2161451182 cites W2165031861 @default.
• W2161451182 cites W2171896543 @default.
• W2161451182 doi "https://doi.org/10.1186/1471-2407-12-603" @default.
• W2161451182 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3582626" @default.
• W2161451182 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/23244208" @default.
• W2161451182 hasPublicationYear "2012" @default.
• W2161451182 type Work @default.
• W2161451182 sameAs 2161451182 @default.
• W2161451182 citedByCount "22" @default.
• W2161451182 countsByYear W21614511822013 @default.
• W2161451182 countsByYear W21614511822014 @default.
• W2161451182 countsByYear W21614511822016 @default.
• W2161451182 countsByYear W21614511822017 @default.
• W2161451182 countsByYear W21614511822018 @default.
• W2161451182 countsByYear W21614511822019 @default.
• W2161451182 countsByYear W21614511822021 @default.
• W2161451182 countsByYear W21614511822022 @default.
• W2161451182 countsByYear W21614511822023 @default.
• W2161451182 crossrefType "journal-article" @default.
• W2161451182 hasAuthorship W2161451182A5018378577 @default.
• W2161451182 hasAuthorship W2161451182A5018425028 @default.
• W2161451182 hasAuthorship W2161451182A5019588141 @default.
• W2161451182 hasAuthorship W2161451182A5019999619 @default.
• W2161451182 hasAuthorship W2161451182A5021493534 @default.
• W2161451182 hasAuthorship W2161451182A5030957656 @default.
• W2161451182 hasAuthorship W2161451182A5041410352 @default.
• W2161451182 hasAuthorship W2161451182A5044903892 @default.
• W2161451182 hasAuthorship W2161451182A5050228664 @default.
• W2161451182 hasAuthorship W2161451182A5056064173 @default.
• W2161451182 hasAuthorship W2161451182A5073713547 @default.
• W2161451182 hasAuthorship W2161451182A5089385974 @default.
• W2161451182 hasBestOaLocation W21614511821 @default.
• W2161451182 hasConcept C121608353 @default.
• W2161451182 hasConcept C126322002 @default.
• W2161451182 hasConcept C142724271 @default.
• W2161451182 hasConcept C143998085 @default.
• W2161451182 hasConcept C168563851 @default.
• W2161451182 hasConcept C176762198 @default.
• W2161451182 hasConcept C204787440 @default.
• W2161451182 hasConcept C27081682 @default.
• W2161451182 hasConcept C2775930923 @default.
• W2161451182 hasConcept C2776694085 @default.
• W2161451182 hasConcept C2779924295 @default.
• W2161451182 hasConcept C2780580376 @default.
• W2161451182 hasConcept C2780852908 @default.
• W2161451182 hasConcept C2780884295 @default.
• W2161451182 hasConcept C530470458 @default.
• W2161451182 hasConcept C71924100 @default.
• W2161451182 hasConceptScore W2161451182C121608353 @default.
• W2161451182 hasConceptScore W2161451182C126322002 @default.
• W2161451182 hasConceptScore W2161451182C142724271 @default.
• W2161451182 hasConceptScore W2161451182C143998085 @default.
• W2161451182 hasConceptScore W2161451182C168563851 @default.
• W2161451182 hasConceptScore W2161451182C176762198 @default.
• W2161451182 hasConceptScore W2161451182C204787440 @default.
• W2161451182 hasConceptScore W2161451182C27081682 @default.
• W2161451182 hasConceptScore W2161451182C2775930923 @default.
• W2161451182 hasConceptScore W2161451182C2776694085 @default.
• W2161451182 hasConceptScore W2161451182C2779924295 @default.

• next